Patents Issued in August 17, 2017
  • Publication number: 20170232045
    Abstract: It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.
    Type: Application
    Filed: March 29, 2017
    Publication date: August 17, 2017
    Applicant: The University of Tokyo
    Inventors: Kenya Honda, Koji Atarashi, Kikuji Itoh, Takeshi Tanoue
  • Publication number: 20170232046
    Abstract: This invention provides lactic acid bacteria that have one or more effects selected from among fatigue-ameliorating effect, blood circulation-improving effect, stool odor-reducing effect, and growth-promoting effect and that can be used with high safety. This invention further provides a pharmaceutical preparation comprising, as an active ingredient, lactic acid bacteria that have one or more effects selected from among fatigue-ameliorating effect, blood circulation-improving effect, stool odor-reducing effect, and growth-promoting effect. According to the invention, novel lactic acid bacteria belonging to the Enterococcus faecium species having particular mycological properties and exhibiting viability of 40% or higher when freeze-dried in the absence of a dispersion medium and viability of 80% or higher in a probiotic preparation when stored at 40° C.
    Type: Application
    Filed: July 7, 2016
    Publication date: August 17, 2017
    Applicant: KANEKA CORPORATION
    Inventors: Airo TATEGAKI, Taizo KAWABE, Hozumi TANAKA
  • Publication number: 20170232047
    Abstract: Disclosed herein are compositions and methods for regulating redox status and/or reducing oxidative stress in a subject, the methods and compositions comprising TLR agonists comprising bacterial lysates and/or lysate fractions. Also disclosed are compositions and methods comprising bacterial lysates and/or lysate fractions formulated or administered in combination with one or more other therapeutic or pharmaceutical agents.
    Type: Application
    Filed: November 10, 2016
    Publication date: August 17, 2017
    Inventor: Elizabeth McKenna
  • Publication number: 20170232048
    Abstract: Provided is a more effective dental synbiotic lozenge that is intra-orally adhesive. The lozenge contains adhesive prebiotics and excipients, and one or more species of probiotic organisms. While safely adhered to an intra-oral surface, the lozenge dissolves to provide a controlled time-release of the excipients, prebiotics, and probiotic organisms over a period of hours instead of minutes. The lozenge dissolves into a malleable biofilm that includes a natural biofilm formed by the prebiotics and a supplemental biofilm formed by the excipients. The lozenge can be used while sleeping, which can increase probiotic availability exponentially. The result is a lozenge that allows for a smaller, but more diverse, microbial payload that can grow over time such that a fewer number of organisms are needed from the start. In one embodiment, the lozenge contains adhesive prebiotics acacia and inulin, along with additional excipients microcrystalline cellulose, HPMC K15, and sodium alginate.
    Type: Application
    Filed: February 17, 2017
    Publication date: August 17, 2017
    Inventor: STEVEN J. EDWARDS
  • Publication number: 20170232049
    Abstract: The present invention relates to a method for increasing the content of rare ginsenosides in preparing an extract of genus Panax including wild ginseng or ginseng, cambial meristematic cells of genus Panax or an extract thereof, a ginseng extract prepared by the method, cambial meristematic cells (CMCs) of genus Panax or an extract thereof prepared by the method, and to a composition comprising the same.
    Type: Application
    Filed: August 24, 2015
    Publication date: August 17, 2017
    Inventors: Young-Woo Jin, Eun-Kyong Lee, Young Mi Lee, Il Seok Oh
  • Publication number: 20170232050
    Abstract: In one aspect there is provided a liquid herbal composition for relieving some or all of the symptoms of Seasonal Affective Disorder (SAD) and/or Chronic Fatigue Syndrome (CFS) or Myalgic Encephalomyelitis (ME). The liquid herbal composition preferably comprises therapeutically effective amounts of hydroalcoholic extracts of Bilberry, Eyebright, Goldenseal root, Ginkgo leaf, Passion flower and Raspberry leaf. The liquid herbal composition is preferably orally administered on a daily basis.
    Type: Application
    Filed: February 16, 2016
    Publication date: August 17, 2017
    Inventor: David ELLERY
  • Publication number: 20170232051
    Abstract: A pharmaceutical composition or dietary supplement is described that is effective in the treatment and prevention of urinary tract infections, comprising a combination of D-mannose, proanthocyanidins, hydroquinone derivatives and zinc.
    Type: Application
    Filed: August 18, 2015
    Publication date: August 17, 2017
    Applicant: Kolinpharma S.p.A.
    Inventors: Domenico Bijno, Carmine Di Vincenzo, Emanuele Lusenti, Alberto Martina, Ritapaola Petrelli
  • Publication number: 20170232052
    Abstract: Lower iron in blood can be accomplished by checking iron level in blood and taking daily an amount of Psyllium husk predetermined to be effective in reducing iron level in blood. Iron level is monitored. Daily intake of Psyllium husk is stopped or significantly reduced when iron level in blood is detected to be at a desired level.
    Type: Application
    Filed: February 11, 2016
    Publication date: August 17, 2017
    Inventor: Kim A. Anderson
  • Publication number: 20170232053
    Abstract: Stem cell-based therapies can potentially reverse organ dysfunction and diseases but the removal of impaired tissue and reactivation of the program leading to organ regeneration pose major challenges. In mice, a four-day fasting mimicking diet (FMD) induces a step-wise expression of Sox17 and Pdx-1, resembling that observed during pancreatic development and followed by Ngn3-driven generation of insulin-producing ?-cells. FMD cycles restore insulin secretion and glucose homeostasis in both a type 2 and type 1 diabetes mouse models. In human type 1 diabetes pancreatic islets, fasting conditions reduce PKA and mTOR activity and induce Sox2 and Ngn3 expression and insulin production. The effects of the FMD are reversed by IGF-1 treatment and recapitulated by PKA and mTOR inhibition. These results indicate that a FMD promotes the reprogramming of pancreatic cells to restore insulin generation in islets from T1D patients and reverse both T1D and T2D phenotypes in mouse models.
    Type: Application
    Filed: February 15, 2017
    Publication date: August 17, 2017
    Inventors: VALTER D. LONGO, ROBERTA BUONO
  • Publication number: 20170232054
    Abstract: A method of economically producing stable and bio-available glutathione comprising immersing glutathione particles in an edible oil preferably selected from at least one of almond, coconut, grapeseed and olive; reducing the average size of glutathione particles to not more than 50 microns and preferably 1 or less; and adding a de-agglomeration agent comprising at least one selected from surfactants or chelating agents. A method of administering bio-available glutathione, prepared according to the foregoing, to a patient in a desired dose by a method selected from oral, pulmonary, rectal, sublingual, transdermal, and vaginal.
    Type: Application
    Filed: January 6, 2017
    Publication date: August 17, 2017
    Inventors: Wilson M. Shepard, Brad Blum
  • Publication number: 20170232055
    Abstract: Embodiments of the present disclosure provide for ?-AApeptides, ?-AApeptide building blocks, methods of making ?-AApeptides and libraries of ?-AApeptides, methods of screening the ?-AApeptide libraries for desired peptidomimetic activity, and the like. The present disclosure also provides for ?-AApeptides that are inhibitors of A? peptide aggregation, methods of inhibiting and disassembling A? peptide aggregation, methods of inhibiting the toxicity of A? aggregates towards N2a neuroblasotma cells, as well as methods and compounds for treating Alzheimer's disease.
    Type: Application
    Filed: February 22, 2017
    Publication date: August 17, 2017
    Applicant: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Jianfeng Cai, Chuanhai Cao, Haifan Wu, Yaqiong Li, Ge Bai
  • Publication number: 20170232056
    Abstract: The present invention provides compositions comprising water soluble peptides with poor solubility in isotonic solutions which exhibit enhanced bioavailability with reduced adverse effects including injection site reactions. Methods are also disclosed for using such compositions for the treatment of diseases including, but not limited to, cancer, type 2 diabetes, acromegaly, metabolic disorders, endocrine disorders, exocrine tumors, and hormone-related tumors. Methods to reduce adverse injection site reactions and improve bioavailability are also disclosed.
    Type: Application
    Filed: April 14, 2017
    Publication date: August 17, 2017
    Inventor: Michel Afargan
  • Publication number: 20170232057
    Abstract: The present invention relates to an opioid peptide represented by general formula TyrProPhe-X1-TrpGlyGly-X2-ProPro, wherein: X1 is represented by Gly or Lys; X2 is represented by Ile or Val. The invention also relates to pharmaceutical, nutritional and nutraceutical compositions comprising the peptide and to the use of the same for analgesic purposes, and/or for providing a feeling of satiety, and/or for lowering arterial blood pressure in a subject.
    Type: Application
    Filed: August 17, 2015
    Publication date: August 17, 2017
    Applicants: Embrapa- Empresa Brasileira De Pesquisa Agropecuár ia, Fundação Universidade de Brasília (FUB)
    Inventors: Carlos BLOCH JUNIOR, Mariana MAGALHÃES NÓBREGA, Karla Graziella MOREIRA, Márcia Renata MORTARI
  • Publication number: 20170232058
    Abstract: A method of stabilizing linaclotide in a solid dosage form, said method comprising a) preparing a composition of linaclotide, acesulfame and pharmaceutically acceptable excipients and b) converting the composition into a solid dosage form.
    Type: Application
    Filed: August 11, 2015
    Publication date: August 17, 2017
    Applicant: Sun Pharmaceutical Industries Ltd.
    Inventors: Rajamannar Thennati, Shirish Kulkarni, Sanjay Poptani, Vimal Kaneria, T. Nathamani
  • Publication number: 20170232059
    Abstract: The present document relates to the field of pharmaceutical composition comprising oxytocin and/or one or more fragment(s) and/or variant(s) thereof, for use in the treatment and/or prevention of a disorder which is responsive to modulation of the endogenous oxytocin production.
    Type: Application
    Filed: October 11, 2013
    Publication date: August 17, 2017
    Inventor: Kerstin Uvnäs-Moberg
  • Publication number: 20170232060
    Abstract: This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.
    Type: Application
    Filed: June 23, 2016
    Publication date: August 17, 2017
    Inventors: Jutta HEIM, Peter SCHNEIDER, Patrick ROUSSEL, Daniel MILLIGAN, Christian BARTELS, Glenn DALE
  • Publication number: 20170232061
    Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.
    Type: Application
    Filed: December 19, 2016
    Publication date: August 17, 2017
    Inventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang, Maryam Rashidi
  • Publication number: 20170232062
    Abstract: This invention relates to a protein C1ORF32 and its variants and fragments and fusion proteins thereof, and methods of use thereof for immunotherapy, and drug development, including but not limited to as immune modulators and for immune therapy, including for autoimmune disorders.
    Type: Application
    Filed: April 30, 2016
    Publication date: August 17, 2017
    Applicant: Compugen Ltd.
    Inventors: Galit ROTMAN, Iris HECHT, Zurit LEVINE, Joseph R. PODOJIL, Stephen D. MILLER
  • Publication number: 20170232063
    Abstract: Casein compositions for increasing the rate of gastric emptying following ingestion of the composition, increasing the digestibility of a protein composition, or increasing the rate of delivery of amino acids to the blood, or for increasing the blood serum concentration of free leucine in a subject, preferably to substantially the same level as whey protein, the casein being about 10 to about 100% calcium depleted, having a degree of hydrolysis less than about 1% and having an unmodified phosphorylation pattern.
    Type: Application
    Filed: January 31, 2017
    Publication date: August 17, 2017
    Inventors: Aaron Calvin Fanning, Hasmukh Ambalal Patel, Johannes Schalk, Ramon Stafford Hall, Roger Richard Schwarzenbach, Sergey Yevgenievich Ukraintsev
  • Publication number: 20170232064
    Abstract: Histatins may be used for skin wound healing in humans and other animals. For example, histatins could be included in gels, ointments, creams, tissue glues, patches, aerosol sprays, subcutaneous injections, subcutaneous infusions, intradermal injections, intradermal infusions, or any combination of these formulations. In some embodiments, peptide fragments from at least two different histatins are used.
    Type: Application
    Filed: October 8, 2015
    Publication date: August 17, 2017
    Inventors: Robert P. Sambursky, Robert W. Vandine, Peter Condon, Uma Mahesh Babu
  • Publication number: 20170232065
    Abstract: Compositions and methods for promoting epithelial tissue regeneration to treat an oral or oropharyngeal wound, e.g., after tonsillectomy are disclosed. In particular, the invention relates to compositions comprising heparin binding epidermal growth factor like growth factor and their use in the treatment of an oral or oropharyngeal wound, e.g., post-therapy treatment to promote epithelial tissue regeneration in wounds, e.g., wounds resulting from surgical removal of tonsil tissue during tonsillectomy procedures, such as palatal, pharyngeal or lingual tonsillectomy. Additionally, HB-EGF can also be used after an adenoidectomy, a procedure sometimes combined with a tonsillectomy, to promote healing of wounds caused by surgical removal of adenoid tissue.
    Type: Application
    Filed: April 20, 2017
    Publication date: August 17, 2017
    Inventors: Peter Luke Santa Maria, Chloe Domville-Lewis, Daniel Beswick, Robson Capasso
  • Publication number: 20170232066
    Abstract: The present invention provides peptides and peptide analogs that have tissue protective activities while having little or no potentially undesirable hematopoietic effects. The peptides and peptide analogs are useful in preventing and treating a variety of diseases and disorders associated with tissue damage.
    Type: Application
    Filed: January 30, 2017
    Publication date: August 17, 2017
    Inventors: Anthony CERAMI, Michael BRINES
  • Publication number: 20170232067
    Abstract: Provided herein are pharmaceutical compositions, formulations and dosage forms comprising variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics). Methods of using the pharmaceutical compositions, formulations and dosage forms are also provided herein.
    Type: Application
    Filed: October 22, 2015
    Publication date: August 17, 2017
    Inventors: Darrin Anthony LINDHOUT, Charles V. OLSON
  • Publication number: 20170232068
    Abstract: Disclosed are the use of neuregulin proteins in preparing a medicine for preventing, treating or delaying preserved ejection fraction cardiac failure in mammals, and a method for using the medicine. Also provided in the present invention is a method for preventing, treating or delaying preserved ejection fraction cardiac failure in mammals, comprising using the medication containing the neuregulin proteins in a special population having the disease or being at risk of having the disease.
    Type: Application
    Filed: October 8, 2015
    Publication date: August 17, 2017
    Inventor: Mingdong Zhou
  • Publication number: 20170232069
    Abstract: The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor and antimicrobial agents for the treatment, pre-emptive treatment or prevention of infectious peritonitis or intra-abdominal infection by intraperitoneal administration of the compositions.
    Type: Application
    Filed: August 7, 2015
    Publication date: August 17, 2017
    Inventors: Lars Heslet, Lars Otto Uttenthal
  • Publication number: 20170232070
    Abstract: The present invention includes a method of treating prostate cancer in a human subject in need thereof, comprising administering to the subject an effective amount of a composition comprising interleukin-2 (IL2), and administering to the subject a cell expressing a chimeric antigen receptor (CAR) which specifically binds prostate specific membrane antigen (PSMA), thereby treating prostate cancer in the human subject in need thereof.
    Type: Application
    Filed: October 24, 2016
    Publication date: August 17, 2017
    Inventor: Richard P. Junghans
  • Publication number: 20170232071
    Abstract: Interferon therapy is improved by concomitant administration of an agent which minimizes the ability of interferon to up-regulate expression of Programmed Cell Death Protein 1 (also known as CD279).
    Type: Application
    Filed: February 11, 2017
    Publication date: August 17, 2017
    Applicant: FKD Therapies Limited
    Inventor: Nigel PARKER
  • Publication number: 20170232072
    Abstract: This document provides methods and materials for treating cardiovascular and/or renal diseases. For example, AAV9 vectors designed to express natriuretic polypeptides, nucleic acid molecules encoding natriuretic polypeptides, methods for making AAV9 vectors, and methods for using such vectors or molecules to treat cardiovascular and/or renal diseases are provided.
    Type: Application
    Filed: February 17, 2017
    Publication date: August 17, 2017
    Inventors: Yasuhiro Ikeda, Stephen James Russell, Alessandro Cataliotti, John C. Burnett, Jr., Jason M. Tonne
  • Publication number: 20170232073
    Abstract: Provided is an incretin, or analogue thereof, an incretin receptor agonist, an incretin enhancer, or any combination thereof, for use in a method of reducing elevated intracranial pressure (ICP) in a subject. Methods of reducing elevated ICP in a subject may comprise administering an incretin, or analogue thereof, an incretin receptor agonist, an incretin enhancer, or any combination thereof to the subject. The elevated ICP may be associated with idiopathic intracranial hypertension (IIH), secondary pseudotumour cerebri, hydrocephalus, normal pressure hydrocephalus, raised intracranial pressure secondary to a brain tumour, meningitis, brain trauma, brain injury, and venous sinus thrombosis.
    Type: Application
    Filed: August 25, 2015
    Publication date: August 17, 2017
    Applicant: The University of Birmingham
    Inventor: Alex Sinclair
  • Publication number: 20170232074
    Abstract: An improved device and method for extended repair and regeneration of muscle tissue. An exemplary device comprises (a) a scaffold comprising an ECM component; (b) a combination of growth factors such as VEGF and IGF; and (c) a population of myogenic cells. Implantation of the device leads to muscle regeneration and repair over an extended period of time.
    Type: Application
    Filed: February 17, 2017
    Publication date: August 17, 2017
    Inventors: David J. Mooney, Cristina Borselli, Herman Vandenburgh, Eduardo Silva, Lin Wang, I, Dmitry Shvartsman, Hannah Storrie, Jeff Lichtman
  • Publication number: 20170232075
    Abstract: The invention provides compositions and methods useful for the treatment and prevention of conditions associated with short telomere length.
    Type: Application
    Filed: August 4, 2015
    Publication date: August 17, 2017
    Inventors: Maria BOBADILLA, Ivan FORMENTINI, Maria Antonia BLASCO MARHUENDA, Christian BAER, Fàtima BOSCH I TUBERT
  • Publication number: 20170232076
    Abstract: A targeted therapeutic including a lysosomal enzyme and a lysosomal targeting moiety that is a peptide containing at least one N-linked glycosylation site. Methods of producing the targeted therapeutic may include nucleotide acids encoding the same and host cells co-expressing GNPT. Pharmaceutical compositions comprising the targeted therapeutic and methods of using the same to treat a lysosomal storage disease.
    Type: Application
    Filed: August 11, 2015
    Publication date: August 17, 2017
    Inventors: Michael F. CONCINO, Bettina STRACK-LOGUE, Muthuraman MEIYAPPAN, Angela W. NORTON, Bohong ZHANG, Andrea ISKENDERIAN, Lieh Yoon LOW, Dianna LUNDBERG, Alla ROMASHKO, Hicham NAIMY
  • Publication number: 20170232077
    Abstract: The invention described herein relates to methods and compositions for treatment of one or more symptoms of gluten intolerance and related conditions (e.g., celiac disease and gluten sensitivity) by administration of a pharmaceutical composition comprising one or more Nepenthes enzymes.
    Type: Application
    Filed: December 16, 2016
    Publication date: August 17, 2017
    Applicant: NEPETX, LLC
    Inventors: David C. Schriemer, Martial Rey
  • Publication number: 20170232078
    Abstract: Provided are compositions and methods for prophylaxis and/or therapy of ErbB1-positive cancer. The compositions include pharmaceutical preparations that contain isolated or recombinant or modified peptidase D (PEPD) proteins. The methods include prophylaxis and/or therapy of ErbB1-positive cancer by administering a PEPD to an individual who has or is at risk for developing ErbB1-positive cancer.
    Type: Application
    Filed: August 20, 2015
    Publication date: August 17, 2017
    Inventors: Yuesheng ZHANG, Lu YANG, Yun LI, Arup BHATTACHARYA
  • Publication number: 20170232079
    Abstract: The present subject matter is directed to a method of manufacturing and purifying an intravenous injection of prothrombin complex concentration (PCC) from plasma Fraction III and a method of manufacturing and purifying an intravenous injection of non-PCC from plasma Fraction IV. The intravenous injection of PCC and non-PCC obtained from the method can be administered to a patient in need thereof for stopping replication, killing and preventing HIV-1 and HIV-2 in a patient.
    Type: Application
    Filed: October 6, 2016
    Publication date: August 17, 2017
    Inventor: Kieu Hoang
  • Publication number: 20170232080
    Abstract: The present invention provides a method for treating a patient for migraine headache, including symptoms associated with migraine head ache, such as migraine associated vertigo, which comprises administering to the patient a therapeutically effective amount of an invertebrate presynaptic neurotoxin, e.g. Botulinum toxin in a pharmaceutically safe form.
    Type: Application
    Filed: April 28, 2017
    Publication date: August 17, 2017
    Applicant: Miotox, LLC
    Inventor: William J. Binder
  • Publication number: 20170232081
    Abstract: An isolated and purified peptide, neonatal NET-inhibitory Factor (nNIF), is disclosed. Methods for treatment of and prophylaxis against inflammatory disorders are also disclosed, including methods of treatment of and prophylaxis against inflammatory disorders comprising administering NET-inhibitory peptides (NIPs), which may be a nNIF, a pharmaceutically acceptable salt of a nNIF, a nNIF analog, a pharmaceutically acceptable salt of a nNIF analog, a nNIF-Related Peptide (nNRP), including the nNRP, Cancer-Associated SCM-Recognition, Immune Defense Suppression, and Serine Protease Protection Peptide (CRISPP), a pharmaceutically acceptable salt of a nNRP, a nNRP analog, or a pharmaceutically acceptable salt of a nNRP analog, to an individual.
    Type: Application
    Filed: February 24, 2017
    Publication date: August 17, 2017
    Inventors: Christian Con Yost, Guy A. Zimmerman, Andrew S. Weyrich
  • Publication number: 20170232082
    Abstract: The present invention relates to peptide fragments which have one or more shared and/or similar amino acid sequences to amino acid sequences of specific portions of the 14 kDa protein of S. mansoni (SM14) or related FABPs (Fatty Acid Binding Proteins), the peptide fragments functioning as continuous or discontinuous epitopic regions of the molecule or mimicking its biological activity. More particularly, the present invention relates to a method for constructing active peptide fragments, peptide fragments, immunogenic compositions and diagnostic kits using peptide fragments.
    Type: Application
    Filed: April 28, 2017
    Publication date: August 17, 2017
    Applicant: Fundaçao Oswaldo Cruz - FIOCRUZ
    Inventors: Miriam Tendler, Richard Charles Garratt, Naftale Katz, Andrew John George Simpson, Frank Jefferson Alarcon de Barrientos, Mônica Magno Vilar, Marilia Sirianni dos Santos Almeida
  • Publication number: 20170232083
    Abstract: Provided herein are compositions and methods for treating and/or identifying children having or suspected of having Celiac disease.
    Type: Application
    Filed: April 24, 2015
    Publication date: August 17, 2017
    Applicant: ImmusanT, Inc.
    Inventors: Robert P. Anderson, Jason A. Tye-Din
  • Publication number: 20170232084
    Abstract: The invention provides methods for treating age-related macular degeneration by administering (i) peptide compositions, (ii) regulatory T-cells from the patient or a compatible donor, or (iii) a combination of regulatory T-cells and said peptide compositions. Also provided are methods for diagnosing age-related macular degeneration and monitoring its progression.
    Type: Application
    Filed: May 2, 2017
    Publication date: August 17, 2017
    Applicant: Enzo Biochem Inc.
    Inventors: Robert Nussenblatt, Baoying Liu, Lai Wei, Elazar Rabbani, James J. Donegan
  • Publication number: 20170232085
    Abstract: The invention relates to minimising the progression of cancer in a companion animal using P2X7 immunotherapy.
    Type: Application
    Filed: December 21, 2016
    Publication date: August 17, 2017
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • Publication number: 20170232086
    Abstract: Described herein is a reliable method for preparing a potent vaccine useful for immunotherapy comprising the step of cryopreserving a population of cells undergoing immunogenic cell death, and using such cells to activate dendritic cells for use in immunotherapy. In a specific embodiment, the method comprises cryopreserving cancer cells undergoing cell death, which can be used to prepare a pharmaceutical composition for immunotherapy against cancer.
    Type: Application
    Filed: December 22, 2016
    Publication date: August 17, 2017
    Inventors: Jitka Fucikova, Lenka Koci, Katerina Pokorna, Iva Truxova, Irena Moserova, Daniela Rozkova, Radek Spisek
  • Publication number: 20170232087
    Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.
    Type: Application
    Filed: April 27, 2017
    Publication date: August 17, 2017
    Inventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
  • Publication number: 20170232088
    Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.
    Type: Application
    Filed: April 27, 2017
    Publication date: August 17, 2017
    Inventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
  • Publication number: 20170232089
    Abstract: A cancer vaccine composition for human leukocyte antigen (HLA)-A*0206-positive persons, comprising a protein product of the tumor suppressor gene WT1 or a partial peptide thereof.
    Type: Application
    Filed: December 16, 2016
    Publication date: August 17, 2017
    Applicant: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
    Inventor: Haruo Sugiyama
  • Publication number: 20170232090
    Abstract: Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro.
    Type: Application
    Filed: May 1, 2017
    Publication date: August 17, 2017
    Inventors: MICHAEL J. P. LAWMAN, PATRICIA D. LAWMAN, MEGHAN GENTILINI, VIJAY RAMIYA, MARINA VICTOR ABDELMASEEH BASTAWROUS, MICHAEL J. SHAMBLOTT
  • Publication number: 20170232091
    Abstract: The present invention provides polypeptides useful as antigens expressed at the pre-erythrocytic stage of the malaria parasite. The antigens can be utilized to induce an immune response and sterile protection against malaria in a mammal by administering the antigens in vaccine formulations or expressing the antigens in DNA or other recombinant protein expression systems delivered as a vaccine formulation.
    Type: Application
    Filed: February 13, 2017
    Publication date: August 17, 2017
    Applicant: CAMRIS International, Inc.
    Inventor: Joao Carlos Aguiar
  • Publication number: 20170232092
    Abstract: Among the various aspects of the present disclosure is the provision of a method of treating an inflammatory bowel disease. Another aspect provides the provision of a screening method for therapeutic agents. Another aspect provides a method of detecting Treg cells to determine if a subject has an inflammatory disease. The present disclosure provides for methods of treatment, diagnosis, and screening for drugs for colitis and ileitis.
    Type: Application
    Filed: February 13, 2017
    Publication date: August 17, 2017
    Applicants: Washington University, California Institute of Technology
    Inventors: Herbert W. Virgin, IV, Hiutung Chu, Sarkis K. Mazmanian
  • Publication number: 20170232093
    Abstract: Provided herein are host cells capable of producing hybrid oligosaccharides and polysaccharides, wherein said hybrid oligosaccharides and polysaccharides do not comprise a hexose at the reducing end of their first repeat unit. Also provided herein are hybrid oligosaccharides or polysaccharides and bioconjugates which can be produced by the host cells described herein, wherein said bioconjugates comprise a carrier protein linked to a hybrid oligosaccharide or polysaccharide that does not comprise a hexose at the reducing end of its first repeat unit.
    Type: Application
    Filed: August 6, 2015
    Publication date: August 17, 2017
    Applicant: Glycovaxyn AG
    Inventor: Amirreza FARIDMOAYER
  • Publication number: 20170232094
    Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of a different subtype, the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of a different subtype, or the prevention or treatment of a disease caused by an infection with PCV2 of a different subtype.
    Type: Application
    Filed: April 27, 2017
    Publication date: August 17, 2017
    Inventors: Gregory HAIWICK, Marc Allan EICHMEYER, Luis Alejandro HERNANDEZ, Wesley Scott JOHNSON, Christine Margaret MUEHLENTHALER, Eric Martin VAUGHN